The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls

被引:91
|
作者
Parish, Sarah [1 ]
Peto, Richard
Palmer, Alison
Clarke, Robert
Lewington, Sarah
Offer, Alison
Whitlock, Gary
Clark, Sarah
Youngman, Linda
Sleight, Peter
Collins, Rory
机构
[1] Univ Oxford, Clin Trial Serv Unit, Oxford OX3 7LF, England
基金
英国医学研究理事会;
关键词
Myocardial infarction; Lipoproteins; Lipids; Cholesterol; Risk factors; CHEMISTRY STANDARDIZATION PROJECT; INTERNATIONAL-FEDERATION; CARDIOVASCULAR-DISEASE; HEART-DISEASE; A-I; PLASMA; COMPARABILITY; LIPOPROTEINS; ASSOCIATIONS; THERAPY;
D O I
10.1093/eurheartj/ehp221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasma levels of apolipoprotein B (apoB), the main surface protein on LDL particles, and LDL-C, the amount of cholesterol in those particles, are closely correlated and, considered separately, are positive risk factors. Plasma levels of apolipoprotein A(1), the main surface protein on HDL particles, and HDL-C, the amount of cholesterol in those particles, are also closely correlated with each other and, considered separately, are negative risk factors. The interdependence of these four risk factors is unclear. Case-control study among 3510 acute myocardial infarction patients (without prior vascular disease, diabetes, or statin use) in UK hospitals and 9805 controls. Relative risks (age, sex, smoking, and obesity-adjusted) were more strongly related to apoB than to LDL-C and, given apoB, more strongly negatively related to apoA(1) than to HDL-C. The ratio apoB/apoA(1) was uncorrelated with time since symptom onset in cases, was reproducible in samples collected a few years apart in controls (correlation 0.81), and encapsulated almost all the predictive power of these four measurements. Its effect was continuous, substantial throughout the UK normal range [relative risk, top vs. bottom decile of this ratio, 7.3 (95% CI 5.8-9.2)] and varied little with age. The ratio apoB/apoA(1) was substantially more informative about risk (chi 12 = 550) than were commonly used measures such as LDL-C/HDL-C, total/HDL cholesterol, non-HDL cholesterol, and total cholesterol (chi 12 = 407, 334, 204, and 105, respectively). Given apoB and apoA(1), the relationship with risk of LDL-C was reversed, and this reversal was strengthened by appropriate allowance for random measurement errors in two correlated variables. Given usual apoB, lower LDL-C (consistent with smaller LDL particles) was associated with higher risk (P < 0.0001). During the first 8 h after symptom onset HDL-C increased by about 10%, precluding reliable assessment of the joint relationship of apoA(1) and pre-onset HDL-C with risk in such retrospective case-control studies. Apolipoprotein ratios are more informative about risk than lipid fractions are. This suggests that, among lipoprotein particles of a particular type (LDL or HDL), some smaller and larger subtypes differ in their effects on risk. Direct measurements of even more specific subtypes of lipoprotein particles may be even more informative about risk.
引用
收藏
页码:2137 / 2146
页数:10
相关论文
共 49 条
  • [1] Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment
    Carr, Stuart S.
    Hooper, Amanda J.
    Sullivan, David R.
    Burnett, John R.
    PATHOLOGY, 2019, 51 (02) : 148 - 154
  • [2] Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk
    Holewijn, S.
    den Heijer, M.
    Swinkels, D. W.
    Stalenhoef, A. F. H.
    de Graaf, J.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (06) : 567 - 577
  • [3] Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1
    Kim, Se Won
    Jee, Jae Hwan
    Kim, Hye Jeong
    Jin, Sang-Man
    Suh, Sunghwan
    Bae, Ji Cheol
    Kim, Sun Wook
    Chung, Jae Hoon
    Min, Yong-Ki
    Lee, Myung-Shik
    Lee, Moon-Kyu
    Kim, Kwang-Won
    Kim, Jae Hyeon
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 2678 - 2683
  • [4] Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
    Johannesen, Camilla Ditlev Lindhardt
    Mortensen, Martin Bodtker
    Langsted, Anne
    Nordestgaard, Borge Gronne
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (11) : 1439 - 1450
  • [5] Soy Protein Reduces Serum LDL Cholesterol and the LDL Cholesterol:HDL Cholesterol and Apolipoprotein B:Apolipoprotein A-I Ratios in Adults with Type 2 Diabetes
    Pipe, Elizabeth A.
    Gobert, Colleen P.
    Capes, Sarah E.
    Darlington, Gerarda A.
    Lampe, Johanna W.
    Duncan, Alison M.
    JOURNAL OF NUTRITION, 2009, 139 (09) : 1700 - 1706
  • [6] Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non-HDL cholesterol and LDL cholesterol
    Walldius, Goran
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (06) : 549 - 551
  • [7] Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease
    Vaverkova, Helena
    Farnier, Michel
    Averna, Maurizio
    Missault, Luc
    Viigimaa, Margus
    Dong, Qian
    Shah, Arvind
    Johnson-Levonas, Amy O.
    Brudi, Philippe
    CLINICAL BIOCHEMISTRY, 2011, 44 (8-9) : 627 - 634
  • [8] Discordance analyses comparing LDL cholesterol, Non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation
    Johannesen, Camilla Ditlev Lindhardt
    Mortensen, Martin Bodtker
    Nordestgaard, Borge Gronne
    Langsted, Anne
    ATHEROSCLEROSIS, 2025, 403
  • [9] Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
    Yun, Yeo-Min
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (03) : 221 - 222
  • [10] Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis
    Vaverkova, Helena
    Karasek, David
    Novotny, Dalibor
    Jackuliakova, Dagmar
    Lukes, Jiri
    Halenka, Milan
    Frohlich, Jiri
    CLINICAL BIOCHEMISTRY, 2009, 42 (12) : 1246 - 1251